ReviewBMJ oncology2026
Beyond stage and HPV status: the evolving landscape and future of multidisciplinary deintensification in human papillomavirus-related oropharyngeal cancer.
Review in BMJ oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rising incidence of oropharyngeal cancer (OPC), primarily driven by human papillomavirus (HPV), presents a significant public health challenge. Given the markedly better prognosis associated with HPV-positive OPC, there is a compelling need to balance oncologic efficacy and reduce treatment morbidity. Although early de-escalation trials did not change standards, selective, biomarker-informed strategies show promise. This review synthesises evidence across transoral robotic surgery (TORS), reductions in RT dose and elective volumes, systemic therapy modification and the integration of circulating HPV DNA, immune profiling and functional imaging to guide truly personalised de-escalation. Ultimately, successful deintensification will require integration of biomarkers, multidisciplinary collaboration and patient-centred decision-making, moving beyond stage and HPV status alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.